BioCardia (BCDA) said Friday that Emory University School of Medicine in Atlanta has started enrolling patients with ischemic heart failure in the company's ongoing phase 3 CardiAMP HF II trial.
The CardiAMP HF II therapy is a system designed for the harvest, processing and minimally invasive delivery of autologous mononuclear cells to the heart intended to enhance microvascular density and reduce fibrosis, the company said.
The study will compare treatment with CardiAMP therapy to a placebo procedure with all patients on stable guideline directed medical therapy, the company said.
Price: 1.95, Change: +0.02, Percent Change: +1.19
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。